KINACEPT
Novel anti-inflammatory compounds for autoimmune diseases
| Coordinatore | SYNOVO GMBH
Organization address
address: Paul Ehrlich Str 15 contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Sito del progetto | http://www.medizin3.uk-erlangen.de/e1846/e623/e719/index_ger.html |
| Totale costo | 1˙475˙995 € |
| EC contributo | 1˙041˙700 € |
| Programma | FP7-SME
Specific Programme "Capacities": Research for the benefit of SMEs |
| Code Call | FP7-SME-2007-1 |
| Funding Scheme | BSG-SME |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-12-01 - 2010-11-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
SYNOVO GMBH
Organization address
address: Paul Ehrlich Str 15 contact info |
DE (TUEBINGEN) | coordinator | 0.00 |
| 2 |
CAIR BIOSCIENCES GMBH
Organization address
address: PAUL EHRLICHSTRASSE 15 contact info |
DE (TUBINGEN) | participant | 0.00 |
| 3 |
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Organization address
address: GESCHWISTER-SCHOLL-PLATZ contact info |
DE (TUEBINGEN) | participant | 0.00 |
| 4 |
EPISTEM LTD
Organization address
address: GRAFTON STREET INCUBATOR BLDG 48 contact info |
UK (MANCHESTER) | participant | 0.00 |
| 5 |
FRIEDRICH-ALEXANDER-UNIVERSITAT ERLANGEN NURNBERG
Organization address
address: SCHLOSSPLATZ 4 contact info |
DE (ERLANGEN) | participant | 0.00 |
| 6 |
INTE:LIGAND SOFTWARE-ENTWICKLUNGS- UND CONSULTING GMBH
Organization address
address: Clemens-Maria Hofbauer Gasse 6 contact info |
AT (MARIA ENZERSDORF) | participant | 0.00 |
| 7 |
QUEEN MARY UNIVERSITY OF LONDON
Organization address
address: 327 MILE END ROAD contact info |
UK (LONDON) | participant | 0.00 |
| 8 |
ROBERT BOSCH GESELLSCHAFT FUR MEDIZINISCHE FORSCHUNG MBH
Organization address
address: AUERBACHSTRASSE 112 contact info |
DE (STUTTGART) | participant | 0.00 |
| 9 |
UNIVERSITA DEGLI STUDI DI PERUGIA
Organization address
address: PIAZZA DELL' UNIVERSITA 1 contact info |
IT (PERUGIA) | participant | 0.00 |
| 10 |
USTAV MOLEKULARNI GENETIKY AKADEMIE VED CESKE REPUBLIKY VEREJNA VYZKUMNA INSTITUCE
Organization address
address: VIDENSKA 1083 contact info |
CZ (PRAHA 4) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The consortium has a lead series of p38 inhibitors with unusual anti-inflammatory properties. The drug leads were originally elaborated as a potential therapy for inflammatory bowel disease, however, the potency of the compounds and their general anti-inflammatory mode of action has raised the possibility of studying their utility in other diseases including rheumatoid arthritis. In addition, feedback from licensing partners has indicated that clear activity in a range of other disease models would dramatically increase interest. A key issue in bringing substances of this class to the clinic is variable patient response to p38 inhibitors in previous trials. Data to date have indicated that there is a potential groups of responders for whom therapy with this class is highly beneficial. The effect of non-responders has, however, made trial outcomes to variable to warrant further development. To solve this problem, we intend to further extend proof-of-concept in patient stratification to allow us to select responder populations for initial patient trials. The objectives of the project are, therefore: § To prepare analogs of the existing compounds § Conduct pre-clinical models for rheumatoid arthritis, IBD, sepsis, liver fibrosis and motilin dependent gut stimulation § Examine the activity of the compounds in human tissue explant models § Select a pre-clinical candidate class § Develop a scaled-up process for GMP synthesis of the lead § Conduct a survey of p38 expression in IBD and RA sub-types at various stages of disease and correlate this plasma markers. § Based on results of tissue explant studies and p38 expression, select a patient stratification protocol for phase 2A studies in man.'
Altri progetti dello stesso programma (FP7-SME)
ECOTHERMO (2012)
Innovative green technology for smart energy saving on existing residential buildings with centralized heating/cooling generators
Read MoreIQ-FRESHLABEL (2010)
"Developing novel intelligent labels for chilled and frozen food products, promoting the influence of smart labels application on waste reduction, food quality and safety in the European supply chains"
Read More